Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EC adopts opinion on pioglitazone-containing drugs

Jan. 12, 2012

Lexicon Pharmaceuticals reports topline data from LX-4211/sitagliptin combination trial

Jan. 12, 2012

Isis Pharmaceuticals reports phase I data on ISIS-TTRRx

Jan. 12, 2012

KalVista Pharmaceuticals and JDRF enter partnership

Jan. 11, 2012

Amicus Therapeutics presents results from phase II study in Fabry's disease

Jan. 11, 2012

BioCryst reports on extension phase of BCX-4208 trial

Jan. 11, 2012

Alnylam files ALN-TTR02 CTA with MHRA

Jan. 10, 2012

Phase II trial of diabetes vaccine reaches full enrollment

Jan. 10, 2012

Scientists at Merck & Co. prepare new PRCP inhibitors

Jan. 10, 2012

KAI Pharmaceuticals begins recruitment in second phase II study of KAI-4169

Jan. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...